Drug Profile
Epoetin alfa - Center of Molecular Immunology
Alternative Names: iorEPOCIM; NeuroEPO; NeuroEPO (nasal); Recombinant human erythropoietin - Center of Molecular ImmunologyLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Center of Molecular Immunology
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Cell stimulants; Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
- Phase II Cardiovascular disorders
- Phase I/II Cerebral infarction; Parkinson's disease
Most Recent Events
- 21 Jan 2016 Phase-I/II clinical trials in Cerebral infarction in Cuba (Intranasal)
- 01 Jun 2014 Withdrawn for Anaemia in Brazil (SC)
- 31 May 2014 Launched for Anaemia in Brazil (SC)